PNC-27
p53/HDM-2–penetratin chimeric anticancer peptide — in-vitro oncology; ≠ PNC-28.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. PNC-27 is a chimeric anticancer peptide combining a p53-derived HDM-2-binding segment with a penetratin (Antennapedia) membrane-transduction sequence. PubChem CID 16201774; formula approx. C188H293N53O44S / MW ~4031–4032; CAS 1159861-00-3. Related peptide PNC-28 is a sibling construct — do not merge. This drawer marks papers. It is not use advice.
Bottom line
Evidence is in vitro / ex vivo oncology pore-formation (“poptosis”) work from the Pincus / Michl / Bowne groups: membrane HDM-2 binding, selective tumor-cell necrosis, leukemia and ovarian models, and recent cervical-cancer cell papers. No approved human oncology indication for PNC-27 is assumed in this pack. Nanoparticle conjugates are delivery science, not approvals.
Papers
PMID 20080680 — Sarafraz-Yazdi 2010
Tested: PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding membrane HDM-2.
Does not show: a completed human oncology RCT.
PMID 20182728 — Sookraj 2010
Tested: PNC-27 induces tumor cell lysis as the intact peptide.
Does not show: clinical dosing or labeled indication.
PMID 25117093 — Davitt 2014
Tested: PNC-27 induces necrosis in a poorly differentiated human leukemia cell line dependent on membrane HDM-2 expression.
Does not show: human leukemia trial success.
PMID 28667027 — Alagkiozidis 2017
Tested: synergy between paclitaxel and PNC-27 in ovarian cancer models.
Does not show: approved combination therapy.
PMID 32878773 — Thadi 2020
Tested: targeting membrane HDM-2 by PNC-27 induces necrosis in leukemia cells but not normal hematopoietic cells (in vitro selectivity framing).
Does not show: human safety/efficacy package.
PMID 35625682 — Sarafraz-Yazdi 2022
Tested: chimeric p53-penetratin peptide binds HDM-2 in a p53-like structure, induces selective membrane pores, leads to cancer cell lysis.
Does not show: regulatory approval.
PMID 38802154 — Krzesaj 2024
Tested: PNC-27 interactions with plasma-membrane HDM-2 and mitochondrial membranes causing mitochondrial disruption in cancer cells.
Does not show: human clinical endpoints.
PMID 38927351 — Bowne 2024
Tested: narrative of “poptosis” / peptide-induced transmembrane pore formation as a cancer-cell kill mechanism.
Does not show: a new primary pivotal trial.
PMID 40750238 — Krzesaj 2025
Tested: HDM-2-targeting PNC-27 kills cervical cancer cells but not normal cervical cells (in vitro).
Does not show: cervical cancer clinical approval.
PMID 18931881 — related PNC-28 context (sibling)
Tested: penetratin sequence in anticancer PNC-28 causes tumor cell necrosis (related construct).
Does not show: PNC-27 identity; sibling-object reminder only.
What is not established
Any approved human cancer indication for PNC-27. Equivalence of unlabeled vials to characterized laboratory peptide. Interchangeability with PNC-28. Safety of systemic human use. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
20080680 20182728 25117093 28667027 32878773 35625682 38802154 38927351 40750238 18931881
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.